Drugs / MEDI7247
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03811652 | Dec 2018 → Dec 2019 | castration-resistant prostate carcinoma, colorectal carcinoma, head and neck squamous cell carcinoma, non-small cell squamous lung carcinoma +2 | MedImmune LLC | Completed | No outcome recorded |
| Phase 1 | NCT03106428 | Mar 2017 → Jan 2020 | acute myeloid leukemia, diffuse large B-cell lymphoma, plasma cell myeloma | MedImmune LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Medi7247 | “Subjects with advanced solid tumors will enroll into the respective arms to receive Medi7247 IV at prescribed dose and schedule” NCT03811652 ↗ |
| Known as | Antibody-drug conjugate medi7247 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298033 ↗ |
| Route | Intravenous | “will receive MEDI7247 IV” NCT03106428 ↗ |